Acinterferon alfa (Research-Grade) is a research-grade biosimilar antibody targeting IFNAR1/IFNAR2. Reactivity: Human. Supplied as a liquid. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.
Interferon alpha/beta receptor 1 (IFNAR1/IFNAR2) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes.
Product Name:
Acinterferon alfa (Research-Grade)
SKU:
GXBS02540
Size:
100 µg, 1 mg
Target:
IFNAR1/IFNAR2
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, Functional assay, Research in vivo
Synonyms:
2941004-21-1
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Humanized IgG1-kappa anti-human TCR Vβ6/β10 monomer disulfide bridged to human IL-2 fragment fused via (G4S)2 peptide linker to immunoglobulin G1 Fc fragment.
